Sagent Pharmaceuticals, Inc. Announces the Launch of Doxorubicin Hydrochloride Injection, USP

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SCHAUMBURG, Ill., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Doxorubicin Hydrochloride Injection, USP, an antineoplastic agent, in three vial presentations. According to IMS, for the 12 months ending September 2013, the US market for Doxorubicin Hydrochloride Injection, USP approximated $14 million. As with all products in Sagent's portfolio, Doxorubicin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC